CureVac N.V. (CVAC)
|Net Income (ttm)||-129.12M|
|Day's Range||56.55 - 58.27|
|52-Week Range||43.30 - 151.80|
|Price Target||71.96 (+24.0%)|
|Est. Earnings Date||Nov 15, 2021|
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenz... [Read more...]
In 2020, CureVac's revenue was $48.87 million, an increase of 180.61% compared to the previous year's $17.42 million. Losses were -$129.12 million, 29.3% more than in 2019.Financial Statements
According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 71.96, which is an increase of 23.98% from the latest price.
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would terminate agreements with Celonic Group and Wac...
CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pi...
It isn't likely.
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to...
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX...
CureVac aims to become one of Europe's big suppliers.
Funds will not be safe if invested in this coronavirus stock.
CureVac shares have slipped more than 20% on bad news.
Investors' dreams of a third strong mRNA vaccine may be over.
CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.
CureVac plans to continue work on its Covid-19 vaccine despite disappointing clinical trial results that showed the shot is just 48% effective.
The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48% effectiveness at preventing the disease, wh...
CureVac (NASDAQ: CVAC) shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of...
Things are looking bleak right now, but they might improve with enough time.
CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% at $56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than ...
CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising.
Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.
Morning Stock Movers: Raven, Torchlight, AMC, CureVac
Jun.21 -- Bloomberg's Kailey Leinz runs down the biggest moving stocks in today's pre-market trading.
German financial watchdog BaFin is investigating possible insider trading of vaccine maker's CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, R...
This coronavirus vaccine developer just hit a massive stumbling block.
CureVac BV (NASDAQ:CVAC) shares are trading higher by 14% at $66.16 as the stock rebounds after falling in recent sessions. The stock dipped after the company late Wednesday announced its COVID-19 vacci...
The news may reinforce Moderna's and Pfizer's vaccine-market dominance.
CureVac N.V.'s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported on Thurs...
So what did the stock market do today? All eyes were on a World Bank decision and big moves in RIDE and CVAC stocks.